Clinical Trials Sponsored by Guangzhou Virotech Pharmaceutical Co., Ltd.

Total 4661 results

Guangzhou Virotech Pharmaceutical Co., Ltd.

Recruiting

A Study of Recombinant Oncolytic Virus M1(VRT106) in Patients With Solid Tumors

Solid Tumor

China
Guangzhou Virotech Pharmaceutical Co., Ltd.

Recruiting

A Study of Intravenous M1-c6v1 for Locally Advanced or Metastatic Solid Tumors

Solid Tumor

Japan
Guangzhou Wondfo Biotech Co., Ltd

Suspended

Preview Rapid Strep A Test Method Comparison Study

Strep Throat

United States
Guangzhou Yipinhong Pharmaceutical CO.,LTD

Completed

The Tolerability and Pharmacokinetics Clinical Trial of Metacavir Enteric-coated Capsules in Healthy Adult Volunteers

Chronic Hepatitis B

China
Guangzhou Yipinhong Pharmaceutical CO.,LTD

Completed

The Efficacy and Safety Study of Fuganlin Oral Liquid in Children With Influenza (Acute Upper Respiratory Infection)

Acute Upper Respiratory Infection

China
Guangzhou Yipinhong Pharmaceutical CO.,LTD

Unknown

A Safety/Efficacy Study of Alprostadil Liposomes for Injection to Treat Lower Extremity Arteriosclerosis Obliterans

Arteriosclerosis Obliterans

China
Guangzhou Yipinhong Pharmaceutical CO.,LTD

Unknown

The Safety and Dose-range Study of Metacavir Enteric-coated Capsules in Patients With Chronic Hepatitis B

Chronic Hepatitis B

China
Guangzhou Yipinhong Pharmaceutical CO.,LTD

Completed

Phase IV Trial,The Efficacy and Safety Study of Fuganlin Oral Liquid in Children With Acute Upper Respiratory Infection

Acute Upper Respiratory Infection

China
Guangzhou Patronus Biotech Co., Ltd.
Yantai Patronus Biotech Co., Ltd.

Not yet recruiting

Safety and Immunogenicity of Recombinant COVID-19 Trivalent Protein Vaccine （CHO Cell）LYB002V14 in Booster Vaccination

SARS-CoV-2 | COVID-19 Vaccine

China
Guangzhou Patronus Biotech Co., Ltd.
Yantai Patronus Biotech Co., Ltd.

Active, not recruiting

Safety and Immunogenicity of COVID-19 Vaccine in Population Aged 18 Years and Above

COVID-19

China
Guangzhou Yipinhong Pharmaceutical CO.,LTD

Completed

The Safety and Tolerability of Metacavir Enteric-coated Capsules in Healthy Adult Volunteers

Chronic Hepatitis B

China
Guangzhou Yipinhong Pharmaceutical CO.,LTD

Unknown

The Efficacy and Safety Study of Clindamycin Palmitate Hydrochloride Dispersible Tablet Treatment of Bacterial Vaginosis

Bacterial Vaginosis

China
Guangzhou Yipinhong Pharmaceutical CO.,LTD

Completed

The Tolerability of Alprostadil Liposome for Injection in Healthy Adult Volunteers

Cardiovascular Diseases

China
Guangzhou Patronus Biotech Co., Ltd.
Yantai Patronus Biotech Co., Ltd.

Active, not recruiting

Immunogenicity and Safety of COVID-19 Vaccine as a Booster Vaccination in Population Aged 18 Years and Above

COVID-19

China
Guangzhou Patronus Biotech Co., Ltd.
Yantai Patronus Biotech Co., Ltd.

Not yet recruiting

A Safety and Immunogenicity Trial of a Respiratory Syncytial Virus Vaccine, LYB005 in Healthy Adults

Respiratory Syncytial Virus (RSV) | RSV Infection
Guangzhou Patronus Biotech Co., Ltd.
Yantai Patronus Biotech Co., Ltd.

Recruiting

A Safety and Immunogenicity Trial of the Recombinant Zoster Vaccine （CHO Cell）, LYB004 in Adults Aged 50 to 70 Years

Herpes Zoster

Australia
Guangzhou Patronus Biotech Co., Ltd.
Yantai Patronus Biotech Co., Ltd.

Terminated

Efficacy and Safety of COVID-19 Vaccine as Booster Vaccination in Adults 18 Years of Age or Older

COVID-19

China
Guangzhou Patronus Biotech Co., Ltd.
Yantai Patronus Biotech Co., Ltd.

Withdrawn

Immunogenicity and Safety of COVID-19 Vaccine in Population Aged 18 Years and Above

COVID-19

China
Guangzhou Magpie Pharmaceuticals Co., Ltd.

Not yet recruiting

A Multiple Dose Study to Investigate Safety, Tolerability and Pharmacokinetics of MN-08 Tablets

Pulmonary Arterial Hypertension
Guangzhou Magpie Pharmaceuticals Co., Ltd.

Not yet recruiting

A Multiple Dose Study to Investigate Safety, Tolerability and Pharmacokinetics of TBN

Healthy
Biotech Pharmaceutical Co., Ltd.

Not yet recruiting

Nimotuzumab Combined With Paclitaxel for Recurrent Metastatic Gastric or Esophagogastric Junction Adenocarcinoma (NOTABLE-307)

Gastric or Esophagogastric Junction Adenocarcinoma
Biotech Pharmaceutical Co., Ltd.

Not yet recruiting

Safety and Preliminary Clinical Activity of Itolizumab in ARDS

Acute Respiratory Distress Syndrome
Biotech Pharmaceutical Co., Ltd.

Completed

A Real-world Study of the Efficacy and Safety of Nimotuzumab in Combination With Chemoradiotherapy for LASCCHN (Redbull-1)

Locally Advanced Head and Neck Squamous Cell Carcinoma

China
Biotech Pharmaceutical Co., Ltd.

Completed

Nimotuzumab in Combination With Radiotherapy for Esophageal Cancer

Esophageal

China
Biotech Pharmaceutical Co., Ltd.

Unknown

Nimotuzumab in Combined With Paclitaxel and Cisplatin for Treatment of Metastatic Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinomas

China
Biotech Pharmaceutical Co., Ltd.

Unknown

Pharmacokinetics Study of Nimotuzumab in Patients With Solid Tumors

Solid Tumors

China
Overseas Pharmaceuticals, Ltd.
Guangzhou Health Start Pharmaceutical Techology Co.,Ltd

Not yet recruiting

An Comparative Pharmacokinetic Study of Amlodipine Besylate Controlled-release Tablets,China in Normal, Healthy, Adult, Human Subjects Under Fasting Conditions

Hypertension

China
Biotech Pharmaceutical Co., Ltd.

Not yet recruiting

Nimotuzumab Combined With Trifluridine/Tipiracil in the Treatment of Refractory Metastatic Colorectal Cancer (NOTABLE-308)

Refractory Metastatic Colorectal Cancer
Biotech Pharmaceutical Co., Ltd.

Terminated

Nimotuzumab Plus Docetaxel in Chemotherapy-Refractory/Resistant Patients With Advanced Non-Small-Cell Lung Cancer

Advanced Non-Small Cell Lung Cancer

China
Biotech Pharmaceutical Co., Ltd.

Unknown

Nimotuzumab in Combination With Chemoradiation for Local Advanced Esophageal Squamous Cell Carcinoma

Squamous Cell Carcinoma

China
Biotech Pharmaceutical Co., Ltd.

Completed

Nimotuzumab in Combination With Chemoradiation for Esophageal Cancer

Advanced Esophageal

China
Biotech Pharmaceutical Co., Ltd.

Not yet recruiting

A Study of Nimotuzumab Plus Concurrent Chemoradiotherapy Sequential Maintenance Treatment for Cervical Carcinoma

Cervical Cancer
Biotech Pharmaceutical Co., Ltd.

Not yet recruiting

Safety and Preliminary Clinical Activity of Itolizumab in Dermatomyositis

Dermatomyositis, Adult Type
Biotech Pharmaceutical Co., Ltd.

Recruiting

Safety and Clinical Activity of Itolizumab in aGVHD

Acute Graft Versus Host Disease

China
Biotech Pharmaceutical Co., Ltd.

Recruiting

Nimotuzumab in Combined With Chemoradiotherapy to Treat the Newly Diagnosed Diffuse Intrinsic Pontine Glioma in Children

Diffuse Intrinsic Pontine Glioma

China
Biotech Pharmaceutical Co., Ltd.

Terminated

Tolerability, Safety and Pharmacokinetic Study of Humanized Anti-CD6 Monoclonal Antibody Injection in Chinese Psoriasis

Psoriasis

China
Biotech Pharmaceutical Co., Ltd.

Completed

Phase IIa Study of Nimotuzumab to Treat Colorectal Cancer

Colorectal Cancer

China
Biotech Pharmaceutical Co., Ltd.

Unknown

Nimotuzumab in Combination With Chemoradiation for Nasopharyngeal Cancer

Nasopharyngeal Cancer

China
Biotech Pharmaceutical Co., Ltd.

Unknown

Nimotuzumab in Combination With Radiochemotherapy for Patients With Stage IIIA/IIIB Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

China
Biotech Pharmaceutical Co., Ltd.

Withdrawn

Nimotuzumab in Combination With Cisplatin and Docetaxel for Patients With Advanced Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

China
Biotech Pharmaceutical Co., Ltd.

Unknown

Study of Nimotuzumab in Combination With Neoadjuvant Chemotherapy for Cervical Cancer

Cervical Cancer

China
Biotech Pharmaceutical Co., Ltd.

Unknown

Phase IV Clinical Trial of Nimotuzumab in the Treatment of Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
Hangzhou Sumgen Biotech Co., Ltd.

Recruiting

SG2501 Safety Study in Subjects With Relapsed or Refractory Hematological Malignancies and Lymphoma.

Lymphoma | Hematological Malignancy

United States
Hangzhou Sumgen Biotech Co., Ltd.

Recruiting

An Open-label Study of SG1827 in Subjects With Advanced Solid Tumors (CSG-1827-101)

Advanced Solid Tumors

China
Hangzhou Sumgen Biotech Co., Ltd.

Recruiting

SG1906 for CLDN18.2-Positive Solid Tumors (CSG-1906-101)

Locally Advanced Unresectable or Metastatic Solid Tumors

China
Hangzhou Sumgen Biotech Co., Ltd.

Active, not recruiting

SG301 Safety Study in Subjects With Relapsed or Refractory Multiple Myeloma and Other Hematological Malignancies

Relapsed or Refractory Multiple Myeloma | Hematological Malignancy

China
Hangzhou Sumgen Biotech Co., Ltd.

Recruiting

SG2918 For Advanced Malignant Tumors

Advanced Malignant Tumors

China
Hangzhou Sumgen Biotech Co., Ltd.

Recruiting

SG301-SC Injection Safety Study in Subjects With Systemic Lupus Erythematosus

Systemic Lupus Erythematosus (SLE)

China
Guangzhou Sinogen Pharmaceutical Co., Ltd
Parexel

Recruiting

Study of SGN1 Administered Via Intratumoral Injection in Patients With Advanced Solid Tumor

Advanced Solid Tumor

China, Taiwan
Hangzhou GluBio Pharmaceutical Co., Ltd.

Recruiting

A Study of GLB-001 in Patients With Myeloid Malignancies

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Polycythemia Vera | Essential Thrombocythemia | Myelofibrosis | Myeloid Malignancy

China

Clinical Trials Sponsored by Guangzhou Virotech Pharmaceutical Co., Ltd.

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Cyprus

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations